What two meds should be given to all ACS patients that do not have contraindications?

What two meds should be given to all ACS patients that do not have contraindications?

• A. Beta-blocker and ACE inhibitor
• B. Diuretic and ACE inhibitor
• C. Calcium channel blocker and nitrates
• D. Anticoagulant and antiplatelet

Answer: (A)

The main idea is that, in acute coronary syndrome, starting two drugs that have proven survival benefits as soon as the patient is able and has no contraindications improves outcomes by both stabilizing the heart now and preventing adverse heart remodeling later. A beta-blocker is given because it lowers heart rate, contractility, and blood pressure, which reduces myocardial oxygen demand and helps prevent dangerous arrhythmias. When started early in stable patients, it decreases the risk of reinfarction and death. The key is to use it only if the patient is hemodynamically stable and without contraindications such as significant hypotension, signs of shock, bradycardia, or severe asthma/COPD. An ACE inhibitor is added for its remodeling and survival benefits after myocardial injury. By blocking the renin-angiotensin system, it reduces afterload and prevents adverse ventricular remodeling, especially helpful in patients with reduced LV function or large infarcts. It’s started early if blood pressure is adequate and kidney function is acceptable, with monitoring for kidney function and potassium. Other options either address symptoms without the same universal mortality benefit (like diuretics unless there's fluid overload, calcium channel blockers, nitrates) or depend on bleeding risk and specific indications (anticoagulants and antiplatelets). However, for patients with ACS who have no contraindications, the combination of a beta-blocker and an ACE inhibitor offers broad short- and long-term survival advantages.

The main idea is that, in acute coronary syndrome, starting two drugs that have proven survival benefits as soon as the patient is able and has no contraindications improves outcomes by both stabilizing the heart now and preventing adverse heart remodeling later.

A beta-blocker is given because it lowers heart rate, contractility, and blood pressure, which reduces myocardial oxygen demand and helps prevent dangerous arrhythmias. When started early in stable patients, it decreases the risk of reinfarction and death. The key is to use it only if the patient is hemodynamically stable and without contraindications such as significant hypotension, signs of shock, bradycardia, or severe asthma/COPD.

An ACE inhibitor is added for its remodeling and survival benefits after myocardial injury. By blocking the renin-angiotensin system, it reduces afterload and prevents adverse ventricular remodeling, especially helpful in patients with reduced LV function or large infarcts. It’s started early if blood pressure is adequate and kidney function is acceptable, with monitoring for kidney function and potassium.

Other options either address symptoms without the same universal mortality benefit (like diuretics unless there's fluid overload, calcium channel blockers, nitrates) or depend on bleeding risk and specific indications (anticoagulants and antiplatelets). However, for patients with ACS who have no contraindications, the combination of a beta-blocker and an ACE inhibitor offers broad short- and long-term survival advantages.